Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI

Inclusion Criteria: 65-80 years old Patients undergoing for elective percutaneous coronary intervention Evidence of a personally signed and dated informed consent document Exclusion Criteria: * Patients undergoing emergency percutaneous coronary intervention * Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent statin (such as simvastatin 20mg/d, pruvastatin 40mg/d, fluvastatin 80mg/d or rovastatin 5mg/d ) in the next 6 months, or needing to take fibrates or niacins simultaneously according to investigators' judgment. * LDL-C \< 1.8mmol/L in patients without statin therapy * Endstage congestive heart failure, or LVEF \< 30% * Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL * Myopathy or increased creatine kinase (CK\>2 UNL) * WBC \< 4×109/L or PLT \< 100×109/L * Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L) * Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible to take statin as investigator's judgment * Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic cardiomyopathy, pericardial diseases * Accompanied with malignant disease or other disease, which cause life expectancy \< 6 months * Participating in other interventional clinical trials using drugs or devices * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding